(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/283438 A1

(51) International Patent Classification:
A61K 9/00 (2006.01)

(21) International Application Number:
PCT/US2022/036542

(22) International Filing Date:
08 July 2022 (08.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/220,362 09 July 2021 (09.07.2021) US
63/282,356 23 November 2021 (23.11.2021) US

(71) Applicant: **ASTRAZENECA PHARMACEUTICALS LP** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US).

(72) Inventors: **JOSHI, Vidya**; 121 Oyster Point Blvd, South San Francisco, California 94080 (US). **ARCHBELL, James**; 121 Oyster Point Blvd, South San Francisco, California 94080 (US). **LACHACZ, Kellisa**; 121 Oyster Point Blvd, South San Francisco, California 94080 (US). **LAMPA, Charina**; 121 Oyster Point Blvd, South San Francisco, California 94080 (US). **MELLO, Lauren**; 4222 Emperor Blvd, Suite 250, Durham, North Carolina 27703 (US). **GUTIERREZ, Gertrude**; 121 Oyster Point Blvd, South San Francisco, California 94080 (US). **LECHUGA-BALLESTEROS, David**; 121 Oyster Point Blvd, South San Francisco, California 94080 (US). **TAN, Penny**; 121 Oyster Point Blvd, South San Francisco, California 94080 (US). **RIEBE, Michael**; 121 Oyster Point Blvd, South San Francisco, California 94080 (US).

(74) Agent: **CHEEMA, Sangeeta K.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

(54) Title: COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY




FIG.7

(57) Abstract: Compositions, methods, and systems are provided for pulmonary delivery of active agents via a metered dose inhaler. In some embodiments, the compositions comprise an HFO-1234ze(E) suspension medium, active agent particles, and suspending particles. The active agent particles may comprise one, two, three or four active agent(s) selected from a long-acting muscarinic antagonist (LAMA), a long-acting β2-agonists (LABA), a short-acting beta-agonists (SABA), an inhaled corticosteroid (ICS), and a non-corticosteroid anti-inflammatory agent.

[Continued on next page]

WO 2023/283438 A1

LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*